FDA calendar · August 2022 · built from SEC filings

PDUFA dates August 2022: FDA calendar and catalysts.

Updated Snapshot 20261116T222116ZBuilt

0 PDUFA dates fell in August 2022. The FDA calendar also recorded 23 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

PDUFA dates in August 2022

No PDUFA dates are disclosed for this period as of November 16, 2026.

Download: CSV · JSON · iCal (next 30 days, CC BY 4.0) · Calendar API · All months

August 2022: other FDA decisions and filings

DateDrugCompanyEventIndicationStatusSource
Aug 2022Month disclosedLibervant® (diazepam)AQSTFDA approval—ApprovedSEC 8-K Exhibit 99.1
Aug 2022Month disclosedAUVELITY (dextromethorphan-bupropion)AXSMFDA approvalMDD in adultsApprovedSEC Form 10-K
Aug 2022Month disclosedroluperidone (MIN-101)NERVNDA/BLA submissionnegative symptoms in schizophreniaCompletedSEC Form 10-Q
Aug 2022Month disclosedMVASI® (bevacizumab)OTLKNDA/BLA submission—CompletedSEC Form 10-K
Aug 2022Month disclosedMVASI® (bevacizumab)OTLKComplete Response Letter—CRL issuedSEC Form 10-K
August 2, 2022Lucentis® (ranibizumab)CHRSFDA approvalneovascularApprovedSEC 8-K Exhibit 99.1
August 2, 2022biosimilarCHRSFDA approvalneovascularApprovedSEC Form 10-K
August 2, 2022CIMERLICHRSFDA approval—ApprovedSEC Form 10-K
August 3, 2022Calquence (acalabrutinib)AZNFDA approval—ApprovedopenFDA Drugs@FDA
August 4, 2022Defencath (heparin sodium; taurolidine)CRMDComplete Response Letter—CRL issuedFDA Complete Response Letters
August 10, 2022TABRECTA (capmatinib)NVSLabel expansion—ApprovedopenFDA Drugs@FDA
August 18, 2022Auvelity (bupropion hydrochloride; dextromethorphan hydrobromide)AXSMFDA approval—ApprovedopenFDA Drugs@FDA
August 24, 2022Imbruvica (ibrutinib)ABBVFDA approval—ApprovedopenFDA Drugs@FDA
August 24, 2022Imbruvica (ibrutinib)ABBVLabel expansion—ApprovedopenFDA Drugs@FDA
August 26, 2022LYNPARZA® (olaparib)AZNLabel expansion—ApprovedopenFDA Drugs@FDA
August 26, 2022Pemazyre (pemigatinib)INCYLabel expansion—ApprovedopenFDA Drugs@FDA
August 30, 2022MVASI® (bevacizumab)OTLKNDA/BLA accepted—CompletedSEC Form 10-Q
August 31, 2022Alimta (pemetrexed)LLYLabel expansion—ApprovedopenFDA Drugs@FDA
August 31, 2022Xenpozyme (olipudase alfa-rpcp)SNYFDA approval—ApprovedFDA Novel Drug Approvals

August 2022: dated readouts

DateDrugCompanyEventIndicationStatusSource
Aug 2022Month disclosed—HCMInterim readout—PositiveSEC 8-K Exhibit 99.1
August 22, 2022OXY-101XRTXTopline readout—PositiveSEC 8-K Exhibit 99.1

August 2022: trial starts and primary completions

DateDrugCompanyEventIndicationStatusSource
Aug 2022Month disclosedbuntanetapANVSTrial start—CompletedSEC Form 10-K

1 tracked companies also report earnings in August 2022; each company page lists its date.

Questions

What PDUFA dates are in August 2022?

0 PDUFA dates fell in August 2022. The FDA calendar also recorded 23 other catalysts that month, such as advisory committees and readouts, each quoted from the sponsor’s SEC filing or the FDA.

Can these dates change?

Yes. The FDA can extend a review by three months after a major amendment, and it sometimes acts before the goal date. Each row links the filing the date came from.

Built from primary public sources only: sponsor SEC filings (8-K, EX-99.1, 10-Q, 10-K), the FDA advisory committee calendar, FDA Novel Drug Approvals and Complete Response Letter records, openFDA, and ClinicalTrials.gov (U.S. National Library of Medicine). Every row links the sentence it came from. Dates move; the linked source is authoritative. Not investment or medical advice.

Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Securities and Exchange Commission. Data is reproduced from public SEC filings and datasets. Not investment advice.